| Literature DB >> 24209392 |
Lawrence Korngut1, Gail MacKean, Lisa Casselman, Megan Johnston, Lundy Day, Darren Lam, Diane Lorenzetti, Janet Warner, Nathalie Jetté, Tamara Pringsheim.
Abstract
BACKGROUND: Patient registries represent a well-established methodology for prospective data collection with a wide array of applications for clinical research and health care administration. An examination and synthesis of registry stakeholder perspectives has not been previously reported in the literature.Entities:
Mesh:
Year: 2013 PMID: 24209392 PMCID: PMC4225768 DOI: 10.1186/1471-2288-13-135
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
Figure 1Registry literature review flowchart.
Focus group questions
| 1. | Round-table introductions, including: Why were you interested in coming out to this focus group tonight? | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2. | Generally, what are your thoughts about patient registries? | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3. | Why might you/your family member be interested in participating in a registry? | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 4. | What might concern you about participating in a registry? | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 5. | What are your thoughts about this information and how it is shared (i.e., information included in a worksheet handout)? | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 6. | What words of advice would you give to doctors and other health professionals about inviting patients to participate in a registry? | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Is there anything else you would like to say? |
Motivating factors for patient participation in registries
| 1. | Altruistic attitudes – the perception of benefit to the greater good even beyond immediate individual benefit or the potential for individual benefit [ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2. | That data will be used by responsible people for legitimate purposes – participants desire clear purposes for collecting data and clear methods for its release [ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3. | Advancement in research and the possibility of elucidation of treatment or cure, [ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 4. | Desire for prompt information after diagnosis [ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 5. | Perception of equal communication with health practitioners and researchers [ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 6. | Other factors influencing participation include satisfaction with care, [ |
Focus group participants
| Epilepsy (4) | 9 | 0 | 7 | 2 | |
| Hydrocephalus (1) | | | | | |
| | Muscular dystrophy (1) | | | | |
| | Tourette Syndrome (3) | | | | |
| Dystonia (3) | 0 | 8 | 7 | 1 | |
| Epilepsy (3) | | | | | |
| | MS (2) | | | | |
| ALS (3) | 3 | 7 | 3 | 7 | |
| Huntington’s (2) | | | | | |
| | Parkinson’s (5) | | | | |
| 27 | 12 | 15 | 17 | 10 | |
Group A included only parents of children living with neurological conditions.